Compare AbbVie Inc (ABBV) vs Li Auto Inc (LI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Li Auto Inc — how do they compare? AbbVie Inc trades at $253.75 (market cap $449.91B), while Li Auto Inc trades at $12.19 (market cap $11.78B). The key difference: AbbVie Inc is far larger — about 38.2× Li Auto Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Li Auto Inc pays none. Which is the better fit depends on your goals.
| ABBV | LI | |
|---|---|---|
Market Cap | $449.91B | $11.78B |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $31.80 |
52-Week Low | $184.85 | $11.74 |
Enterprise Value | $513.38B | $693.65M |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
Li Auto (LI) trades at $12.05, near its 52-week low, with a bearish technical outlook. Revenue declined to $112.31B in 2025, and net income fell to $1.12B, reflecting margin pressure. Analyst consensus is mixed with a $14.80 price target, but recent news highlights competitive headwinds and delivery growth of 30,895 vehicles in June 2026.
The stock faces near-term risks from intense EV competition and profitability challenges, but long-term recovery potential exists if L-series execution improves. Investors should weigh low valuation multiples against operational cash flow deficits and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →
